Beyond PrPC capacity to bind pathogenic prions PrPSc in prion diseases [43], amyloid Aβ peptides in Alzheimer’s disease [33], or α-synuclein in Parkinson’s disease [56], our data show that PrPC can also fix with high-affinity (10 to 30 μg ml−1) two types of nanoparticle aggregates, TiO2- and CB-NPs, despite distinct size, chemical compositions and reactive properties [47]. The gene discussed is PRNP; the disease is Parkinson disease.